Quantitative Fundus Autofluorescence in HCQ Retinopathy
Overview
Authors
Affiliations
Purpose: To increase our understanding of the mechanisms underlying hydroxychloroquine (HCQ) retinopathy, analyses by quantitative fundus autofluorescence (qAF) and near-infrared fundus autofluorescence (NIR-AF) were compared to results obtained by recommended screening tests.
Methods: Thirty-one patients (28 females, 3 males) were evaluated with standard automated perimetry and spectral domain optical coherence tomography (SD-OCT); 28 also had multifocal electroretinography (mfERG). Measurement of short-wavelength fundus autofluorescence (SW-AF) by qAF involved the use of an internal fluorescent reference and intensity measurements in eight concentric segments at 7° to 9° eccentricity. For semiquantitative analysis of NIR-AF, intensities were acquired along a vertical axis through the fovea.
Results: Four of 15 high-dose (total dose >1000 g, daily dose >5.0 mg/kg) patients and one of 16 low-dose (total dose <1000 g, daily dose 4.4 mg/kg) patients were diagnosed with HCQ-associated retinopathy based on abnormal 10-2 visual fields, SD-OCT, and SW-AF imaging. Three of the high-dose patients also had abnormal mfERG results. Of the five patients exhibiting retinopathy, two had qAF color-coded images revealing higher intensities inferior, nasal, and lateral to the fovea. The abnormal visual fields also exhibited superior-inferior differences. Mean NIR-AF gray-level intensities were increased in four high-dose patients with no evidence of retinopathy. In two patients with retinopathy, NIR-AF intensity within the parafovea was below the normal range. One high-dose patient (6.25 mg/kg) had only abnormal mfERG results.
Conclusions: These findings indicate that screening for HCQ retinopathy should take into consideration superior-inferior differences in susceptibility to HCQ retinopathy.
Zheng B, Geng Y, Li Y, Huang H, Liu A Ann Hematol. 2024; 103(8):2945-2960.
PMID: 38829410 DOI: 10.1007/s00277-024-05764-2.
Radun V, Berlin A, Tarau I, Kleefeldt N, Reichel C, Hillenkamp J Transl Vis Sci Technol. 2023; 12(7):8.
PMID: 37418250 PMC: 10337803. DOI: 10.1167/tvst.12.7.8.
Review of Retinal Imaging Modalities for Hydroxychloroquine Retinopathy.
Cheong K, Ong C, Chandrasekaran P, Zhao J, Teo K, Mathur R Diagnostics (Basel). 2023; 13(10).
PMID: 37238236 PMC: 10217485. DOI: 10.3390/diagnostics13101752.
Novel imaging techniques for hydroxychloroquine retinopathy.
Yusuf I, Charbel Issa P, Ahn S Front Med (Lausanne). 2022; 9:1026934.
PMID: 36314000 PMC: 9606779. DOI: 10.3389/fmed.2022.1026934.
Retinal microvasculature alteration in patients with systemic sclerosis and chloroquine treatment.
Huang T, Liang R, Zhang L, Shu H, Ge Q, Liao X Quant Imaging Med Surg. 2022; 12(10):4885-4899.
PMID: 36185048 PMC: 9511431. DOI: 10.21037/qims-21-1166.